Elisa Minenza
Azienda Ospedaliera di Perugia · 34 works · 7,483 citations · h-index 13
Top works
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
- Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
- Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
- EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
- Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab
- The safety of nivolumab for the treatment of advanced non-small cell lung cancer
- Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report
- Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women
- Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227
- Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy
- Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women
- Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study
- P1.01-053 Italian Nivolumab Expanded Access Programme (EAP): Data from Patients with Advanced Non-Squamous NSCLC and Brain Metastases
- Longer-Term Follow-Up of a Phase 2 Study (CheckMate 063) of Nivolumab in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
- A novel BRCA1 splicing variant detected in an early onset triple-negative breast cancer patient additionally carrying a pathogenic variant in ATM: A case report
- Phase 2 Study of Nivolumab (ANTI-PROGRAMMED DEATH-1 [PD-1]) in Patients (PTS) with Advanced, Refractory Squamous (SQ) Non-Small Cell Lung Cancer (NSCLC)
- HER2, EGFR, PIK3CA mutations in HER2+ metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response